AU728053B2

AU728053B2 - Precursors of cyclopropylindoles and their use as prodrugs

Info

Publication number: AU728053B2
Application number: AU54192/98A
Authority: AU
Inventors: Graham John Atwell; William Alexander Denny; Jared Milbank; Moana Tercel
Original assignee: Cancer Research Campaign Technology Ltd
Current assignee: Auckland Uniservices Ltd
Priority date: 1996-12-13
Filing date: 1997-12-12
Publication date: 2001-01-04
Anticipated expiration: 2017-12-12
Also published as: GB9625913D0; DK0944596T3; DE69716463T2; PT944596E; AU5419298A; EP0944596A1; WO1998025898A1; CA2272952A1; NZ335841A; EP0944596B1; ES2186006T3; ATE226194T1; JP2001506623A; DE69716463D1

Abstract

The present invention relates to novel amino analogues of the general class of cyclopropylindoles and their seco precursors, and is particularly concerned with the use of these compounds as prodrugs for antibody-directed enzyme-prodrug therapy (ADEPT) and gene-directed enzyme-prodrug therapy (GDEPT) for cancer.

Description

1 PRECURSORS OF CYCLOPROPYLINDOLES AND THEIR USE AS PRODRUGS The present invention relates to novel amino analogues of the general class of cyclopropylindoles and their precursors, and is particularly concerned with the use of these compounds as prodrugs for antibody-directed enzyme-prodrug therapy (ADEPT) and gene-directed enzyme-prodrug therapy (GDEPT) for cancer.

Background to the invention The use of prodrugs represents a clinically very valuable concept in cancer therapy since, particularly where the prodrug is to be converted to an anti-tumour agent under the influence of an enzyme that is linkable to a monoclonal antibody that will bind to a tumour associated antigen, the combination of such a prodrug with such an enzyme monoclonal/antibody conjugate represents a very powerful clinical agent. This approach to cancer therapy, often referred to an "antibody-directed S. enzyme/prodrug therapy" (ADEPT) is disclosed in WO 88/07378.

A further therapeutic approach termed "virus-directed enzyme prodrug therapy" (VDEPT) has been proposed as a method for treating tumour cells in patients using prodrugs. Tumour 20 cells are targeted with a viral vector carrying a gene encoding an enzyme capable of activating a prodrug. The gene may be transcriptionally regulated by tissue specific promoter or enhancer sequences. The viral vector enters tumour cells and expresses the enzyme, in order that a prodrug is converted to an 25 active drug within the tumour cells (Huber et al, Proc. Natl.

Acad, Sci. USA (1991) 88, 8039). Alternatively, non-viral methods for the delivery of genes have been used. Such methods include calcium phosphate co-precipitation, micropinjection, liposomes, direct DNA uptake, and receptor-mediated

DNA

transfer. These are reviewed in Morgan French, Annu. Rev WO 98/25898 PCT/NZ97/00166 2 Biochem., 1993, 62;191. The term "GDEPT" (gene-directed enzyme prodrug therapy) is used to include both viral and non-viral delivery systems.

Cyclopropylindole compounds are a class of highly potent antitumour antibiotics with the natural products CC-1065 (V.L.

Reynolds et al, J. Antibiot., 39, 1986, 319-334) and the duocarmycins Boger, Pure Appl. Chem., 66, 1994, 837-844), having IC50's in the low pM range. These compounds bind in the minor groove of DNA and alkylate in a highly sequence selective manner at N-3 of adenine Boger et al, Tetrahedron, 47, 1991 2661-2682). Studies with compounds that model the alkylation subunit have shown that the more stable open chain seco precursors are as potent as the cyclopropylindole compounds. Further, ring closure is not essential for DNA alkylation, and there is some measure of electronic control by the both the 6-substituent (D.L.

Boger et al, J. Am. Chem. Soc., 113, 1991, 3980-3983) and the 1substituent Boger and W. Yun, J. Am. Chem. Soc., 116, 1994, 5523-5524) on the rate of alkylation.

A number of synthetic analogues of the natural products have been prepared in which the oxygen at the 6-position is protected as a carbamate that must be cleaved (by non-specific enzymatic hydrolysis) for activity. These compounds include carzelesin (L.H.

Li et al, Cancer Res., 52, 1992, 4904-4913) and KW-2189 (E.

Kobayashi et al, Cancer Res., 54, 1994, 2404-2410) which show anticancer activity against a range of human tumours and are in clinical trial. These compounds have the structures A and B respectively: SUBSTITUTE SHEET (RULE 26) WO 98/25898 PCT/NZ97/00166

-CI

HNH

N N A

ON

0 N 0N(CH 2

CH

3 2

H

3 C C0 2 CH1 3

HN

CH

3

(B)

H

3 C-N NCO N1 N CH 3 0

H

OCH

3 Further analogues of a similar type are disclosed in W088/04659 and W091/16324.

SUBSTITUTE SHEET (RULE 26) Description of the drawings Figure 1 shows Scheme 1 for the preparation of compounds of the invention. The steps to (vii) involve the following reactants/conditions: i. Ph 3 P=CHCOOMe /benzene/ ref lux/ 24 h.

ii Malonic acid/piperidine/pyridine/20'C/20 h.

iii Dimethyl sul fate /NaHCO 3 /aqueous MeOH/reflux/l h iv Fe /CBuCO) 2 0/ aqueous MeOH-/reflux/45 min.

v NaOH/aqueous MeOH/reflux/50 min.

vi EDCI.HCl/DMF/40 0 C/16 h.

vii Fe/AcOH/MeOH/water/reflux/40 min.

viii 4-NO 2

C

6

HCH

2 COCl/pyridine/20'C/l.5 h.

Figure 2 shows Scheme 2. The steps to (iii) involve the following/reactants/conditions: i -Mepyrrole--2-carboxylic h.

ii GS 2

CO

3 /aqueous MeOH/reflux/2/5 h iii EDCI.HCl/DMA/20 0 c/2 H.

Disclosure of the invention In one aspect, the present invention relates to the new class of 6-substituted indolines, represented by formula N Ht

C-)

:3,S wherein: X is halogen or OSO 2 R, where R represents H or lower alkyl (up to five carbon atoms) optionally substituted with from 1 to 4 hydroxyl, acid (COOH) or amino groups which amino may be optionally substituted by one or two Ci 1 5 alkyl groups; Y is NO 2

N

3 NHOH, NHR, NRR N=NR, N(O)RR, SR or SSR, where R is defined as above, but that in the case where Y is N+NR or SSR, then R can also be another moiety or formual (I) a or symmetrical disulfide or AZO compound); 0 or Y is a group of formula:

-NR

0 O

(II)

where R is as defined above, and A may be a group CONHR, NHCOR or OR where R is as defined above at any one of positions 2 or 3; Ht is a 5 or 6 membered carbocycle or heterocycle containing up to two atoms selected from N, 0 or S, the carbocycle or heterocycle being optionally substituted by a group Q wherein either Q is one or two of H, OR or NRR where R is defined as above (which may be the same or different when Q is two) or Q is a group CONHJ 1

NHCOJ

1

NHCOOJ

1 or NHCONHJ 1 is either a group R as defined above or a 5 or 6 membered carbocycle or heterocycle containing up to two atoms selected from N, 0 or S and can bear a substituent R, OR, NHCOR, NHCOOR or NHCONHR where R is as defined above; wherein if Ht is a pyrrol-2-yl group, then the pyrrolyl group may bear an N-methyl group; WO 98/25898 PCT/NZ97/00166 6 or a physiologically functional derivative thereof.

It is recognised that compounds of formula may exist in one of two different enantiomeric forms. In such cases it is to be understood that formula represents either enantiomeric form or a mixture of both.

A halogen group means a fluoro, chloro, bromo or iodo group.

A chloro group is preferred. Preferred compounds of formulae (I) include those in which X represents Cl.

Examples of the group Ht include the carbocycle phenyl and the heterocycles pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, furyl, isothiazolyl, thienyl and morpholinyl. It is preferred that Ht be phenyl or pyrrolyl, e.g. pyrrol-2-yl.

Preferred examples of the group Q include NHCOR where R is C,_ 4 alkyl and NHCOJ 1 where J 1 is a heterocycle as defined above, and preferably pyrrol-2-yl, optionally substituted on the nitrogen atom by C 1 4 alkyl.

In another aspect, the present invention relates to the use of the compounds of formula as anticancer drugs. The compounds may be used for the selective killing of oxic and hypoxic tumour cells in methods of treatment of cancers, for example leukemias and particularly solid cancers including breast, bowel and lung tumours, including small cell lung carcinoma.

In a further aspect, the present invention relates to the use of the compounds in which Y is a group of formula in conjunction with nitroreductase enzyme (for example, isolated from E. coli) in methods of ADEPT and GDEPT therapy. Compounds of the formula in which Y is N, 2 or N(O)RR may also be used in conjunction with nitroreductase.

The invention also provides pharmaceutical compositions comprising a compound of the formula together with a pharmaceutically acceptable carrier or diluent.

SUBSTITUTE SHEET (RULE 26) WO 98/25898 PCT/NZ97/nn00166 7 Detailed description of the invention.

In general, compounds of the present invention may be made by reaction of an indoline of formula (IIIa) or (IIIb) x x NH N OtBu No, (IIa) OH (Illb) where X is as defined for formula Compounds of the formula (IIIa) may be reacted with an acid of formula (IV) Ht ""^^COOH

(IV)

where Ht is as defined for formula under conditions suitable for the production of a compound of formula For example, the reaction may be carried out in a polar aprotic solvent such as DMF or DMA, in the presence of a coupling agent 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride].

The compound of formula where Y NO 2 thus obtained may be converted into other compounds of formula by appropriate methods. For example, reduction such as in an alcoholic or aqueous alcoholic solvent with iron powder in the presence of an acid such as acetic acid can be used to prepare compounds of formula where Y

NH,.

Reductive alkylation of componds of formula where Y=NH 2 can be used to form compounds of formula in which Y is NHR or NRR.

For example, formic/acetic anhydride and diborane gives compounds of SUBSTITUTE SHEET (RULE 26) WO 98/25898 PCT/NZ97/00166 8 formula where Y NHMe; formaldehyde/sodium cyanoborohydride gives compounds of formula where Y NMe 2 Controlled hydrogenation of componds of formula where Y=NH 2 in e.g. DMF provides the hydroxylamines (Y NHOH in formula Compounds of formula where Y is NH 2 may also be prepared by reaction of an indoline formula (IIIb), where X is as defined for formula with an acid such as HC1, and coupling of the product with a compound of formula Appropriate conditions for the coupling reaction include polar aprotic solvents such as DMF or DMA and a coupling reagent such as .1-(3-dimethylaminopropyl)-3ethylcarbodiimide hydrochloride (EDCI). Further reaction with: (a) a trifluoromethanesulfonating reagent such as trifluoromethanesulfonic anhydride in the presence of a base triethylamine), then; treatment with benzophenone imine, a base such as cesium carbonate, and a palladium or nickel catalyst and appropriate ligand palladium acetate and 2,2'bis(diphenylphosphino)-1,1'-binaphthyl or tetrakis(triphenylphosphine)palladium], then; mild acid cleavage of the resulting imine, using for example HC1 or acetic acid in a solvent such as THF-water or THF-MeOH-water mixtures, gives the desired compounds of formula where Y= NH 2 Further compounds of formula where Y NHR, where R is defined as above, may be prepared by substituting the appropriate amine H 2 NR or HNRR for benzophenone imine in the above sequence.

The appropriate amines will contain suitably protected forms of the substituents in the R group.

Diazonium chemistry may be used to convert the amino compounds (Y NH2 in formula to the azides (Y N 3 in formula or to sulfur derivatives (Y SR or SSR in formula When Y is a tertiary amine, oxidation (for example with peracids) can be used to provide the corresponding N-oxides (Y SUBSTITUTE SHEET (RULE 26) WO 98/25898 PCT/NZ97/nnl; 9 N(0)RR in formula Acylation of a compound of formula where Y=NHR with a suitably protected substituted 4-nitrobenzyl derivative of formula

(V)

z 2

A

3

(V)

NO

2 or reactive derivative thereof, wherein Z is a halogen, particularly chlorine, and A is as defined for formula in the presence of an added base gives the corresponding acyl analogues of general formula where Y is a group of formula (II).

Suitable reaction conditions include presenting the compound of formula in e.g. THF or dioxane. Suitable bases to be added include Et 3

N.

Compounds of formulae (liIa), (IIIb), (IV) and are either commercially available or may be prepared using known starting materials and published chemical methods, and are further illustrated in the Examples. For compounds of formula (IIIb), reference may also be made to D.L. Boger et al, J. Am. Chem. Soc.

1990, 122; 5230-5240.

Compounds of formula where Q includes a group J 1 may be made by reacting a compound of formula (VIa)

NH

2 Het' (VIa) Mea 2

C

wherein Het' is a 5- or 6-membered carbocycle or heterocycle SUBSTITUTE SHEET (RULE 26) WO98/25898 PCT/NZ97/00166 containing one or two groups N, 0 or S with a compound of formula HO2C-J 1 (or a reactive derivative thereof), or with a compound of formula H 2

N-J

1 or HO-J' in the presence of phosgene (or a reactive phosgene equivalent). J1 is as defined for formula and can bear suitably protected forms of the substituents as defined above.

Other examples of compounds formula (IV) where Q includes a group J 1 may be made by reacting a compound of formula (VIb)

CO

2

H

Het' (VIb) MeO 2 C with a compound of formula H 2

N-J

1 (or a reactive deriative thereof) wherein Het' and J 1 are as defined above.

The methyl ester group in the resulting compounds which derive from the compounds of formulae (VIa) and (VIb) can then be cleaved under standard conditions to give the free acids.

Reference may also be made to Schemes 1 and 2 set out in Figures 1 and 2 respectively. Analogous procedures may be used to obtain other compounds of the invention. The compounds of formula can be prepared by the processes outlined for specific examples in Schemes 1 and 2.

In Scheme 1, nitration of commercially available l-methyl-2pyrrolecarboxaldehyde as described Fournari, Bull. Soc. Chem.

Fr., 1963, 488-491], and crystallisation of the product mixture, gives the 4-nitroaldehyde 1. Wittig reaction of 1 with methyl triphosphorylidene acetate gave the methyl acrylate 2 (which could also be made by a Doebner reaction of 1 with malonic acid to give 3, followed by methylation to Iron dust reduction of 2 in the presence of butyric anhydride gave butyramide 4, which could be hydrolysed to the corresponding acid 5 with aqueous sodium SUBSTITUTE SHEET (RULE 26) WO 98/25898 PCT/NZ97/00166 11 hydroxide. Coupling of the acid 5 with 3-(chloromethyl)-6nitroindoline 6 (prepared from the known 1-(tert-butyloxycarbonyl)- 3-chloromethyl-6-nitro-indoline [see WO 88/04659 and WO 91/16324] gave the nitro-seco-CI analogue 7 (an example of formula where X is Cl, Y is NO 2 and Ht is 4-butyramido-1-methyl-2pyrrolecarboxamido.

In Scheme 2, coupling of methyl trans-3-aminocinnamate 9 and l-methylpyrrole-2-carboxylic acid with EDCI.HC1 in pyridine gave the ester 10, which was hydrolysed to the acid 11 with Cs 2

CO

3 in aqueous MeOH. Coupling of the acid 11 with 3-chloro-methyl-6-nitroindoline 6 gave 1-[(E)-3-(l-methylpyrrole-2-carboxamido)cinnamoyl]-3chloromethyl-6-nitroindoline (12) (an example of formula I where X is Cl, Y is NO 2 and Ht is (E)-3-(l-methylpyrrole-2carboxamido)cinnamoyl.

C. GDEPT C(i) Vector systems In general, the vector for use in GDEPT therapies may be any suitable DNA or RNA vector.

Suitable viral vectors include those which are based upon a retrovirus. Such vectors are widely available in the art. Huber et al (ibid) report the use of amphotropic retroviruses for the transformation of hepatoma, breast, colon or skin cells. Culver et al (Science (1992) 256; 1550-1552) also describe the use of retroviral vectors in GDEPT. Such vectors or vectors derived from them may also be used. Other retroviruses may also be used to make vectors suitable for use in the present invention. Such retroviruses include rous sarcoma virus (RSV).

Englehardt et al (Nature Genetics (1993) j; 27-34) describe the use of adenovirus based vectors in the delivery of the cystic SUBSTITUTE SHEET (RULE 26) WO 98/25898 PCTINZ97/00166 12 fibrosis transmembrane conductance product (CFTR) into cells, and such adenovirus based vectors may also be used. Vectors utilising adenovirus promoter and other control sequences may be of use in delivering a system according to the invention to cells in the lung, and hence useful in treating lung tumours.

Other vector systems including vectors based on the Molony murine leukaemia virus are known (Ram, Z et al, Cancer Research (1993) 51; 83-88; Dalton Treisman, Cell (1992) 68; 597-612).

These vectors contain the Murine Leukaemia virus (MLV) enhancer cloned upstream at a -globin minimal promoter. The 0-globin untranslated region up to the initiation ATG is supplied to direct efficient translation of the enzyme.

Suitable promoters which may be used in vectors described above, include MLV, CMV, RSV and adenovirus promoters. Preferred adenovirus promoters are the adenovirus early gene promoters.

Strong mammalian promoters may also be suitable. An example of such a promoter is the EF-la promoter which may be obtained by reference to Mizushima and Nagata ((1990), Nucl. Acids Res. 18; 5322).

Variants of such promoters retaining substantially similar transcriptional activities may also be used.

C(ii) Nitroreductase Compounds of the formula in which Y is NO 2 N(O)RR, or a group of formula (II) can be activated by reduction of this group by nitroreductase.

Preferably, the enzyme is a non-mammalian nitroreductase enzyme, such as a bacterial nitroreductase. An E.coli nitroreductase as disclosed in W093/08288 is particularly preferred.

The enzyme may be modified by standard recombinant DNA techniques, e.g. by cloning the enzyme, determining its gene sequence and altering the gene sequence by methods such as truncation, SUBSTITUTE SHEET (RULE 26) WO 98/25898 PCT/NZ97/00166 13 substitution, deletion or insertion of sequences for example by site-directed mutagenesis. Reference may be made to "Molecular Cloning" by Sambrook et al (1989, Cold Spring Harbor) for discussion of standard recombinant DNA techniques. The modification made may be any which still leaves the enzyme with the ability to reduce the nitro group in formula I or II but alters other properties of the enzyme, for example its rate of reaction or selectivity.

In addition, small truncations in the N- and/or C-terminal sequence may occur as a result of the manipulations required to produce a vector in which a nucleic acid sequence encoding the enzyme is linked to the various other vector sequences.

D. ADEPT For applications in ADEPT systems, an antibody directed against a tumour specific marker is linked to the nitroreductase enzyme, which may be modified as described above. The antibody may be monoclonal or polyclonal. For the purposes of the present invention, the term "antibody", unless specified to the contrary, includes fragments of whole antibodies which retain their binding activity for a tumour target antigen. Such fragments include Fv, F(ab') and F(ab') 2 fragments, as well as single chain antibodies.

Furthermore, the antibodies and fragments thereof may be humanised antibodies, e.g. as described in EP-A-239400.

The antibodies may be produced by conventional hybridoma techniques or, in the case of modified antibodies or fragments, by recombinant DNA technology, eg by the expression in a suitable host vector of a DNA construct encoding the modified antibody or fragment operably linked to a promoter. Suitable host cells include bacterial (eg. E.coli), yeast, insect and mammalian. When the antibody is produced by such recombinant techniques the enzyme may SUBSTITUTE SHEET (RULE 26) WO 98/25898 PCT/NZ97/00166 14 be produced by linking a nucleic acid sequence encoding the enzyme (optionally modified as described above) to the 3' or 5' end of the sequence of the construct encoding the antibody or fragment thereof.

E. Physiologically functional derivatives Physiologically functional derivatives of prodrugs include salts, amides and esters. Esters include carboxylic acid esters in which the non-carbonyl moiety of the ester grouping is selected from straight or branched chain C 1 6 alkyl, (methyl, n-propyl, n-butyl or t-butyl); or C 3 6 cyclic alkyl cyclohexyl). Salts include physiologically acceptable base salts, eg derived from an appropriate base, such as alkali metal sodium), alkaline earth metal magnesium) salts, ammonium and NR"4 (wherein R" is C 1 4 alkyl) salts. Other salts include acid addition salts, including the hydrochloride and acetate salts. Amides include non-substituted and mono- and di-substituted derivatives. Such derivatives may be prepared by techniques known per se in the art of pharmacy.

F. Applications of the invention Compounds of the invention can be used in vitro or in vivo for a range of applications. For example, a number of vector systems for the expression of nitroreductase in a cell have been developed.

The further development of such systems the development of promoters suitable for specific cell types) requires suitable candidate prodrugs capable of killing cells when activated by nitroreductase. Prodrug compounds of the present invention may be used in such model systems. The model systems may be in vitro model systems or xenograft model systems comprising for example human tumour cells implanted in nude mice.

Compounds of the invention which are not activatable by an .enzyme may be tested in vitro against panels of different tumour SUBSTITUTE SHEET (RULE 26) WO 98/25898 PCT/NZ97/00166 cells types to determine efficacy against such tumour cells. The efficacy of compounds of the invention against a range of tumour cell types may be used as points of reference for the development of further antitumour compounds. Compounds of the present invention may also be tested in combination with additional anti-cancer compounds to determine potential combination drug systems, for example combinations which are synergistic.

The compounds of the invention may also be used in a method of treatment of the human or animal body. Such treatment includes a method of treating the growth of neoplastic cells in a patient with neoplastic disease which comprises administering to a patient in need of treatment compounds of formula of the invention, or compounds of formula (II) of the invention as part of an ADEPT or GDEPT therapy system. Neoplastic diseases include leukaemia and solid tumours such as breast, bowel and lung tumours including small cell lung carcinoma.

It will be understood that where treatment of tumours is concerned, treatment includes any measure taken by the physician to alleviate the effect of the tumour on a patient. Thus, although complete remission of the tumour is a desirable goal, effective treatment will also include any measures capable of achieving partial remission of the tumour as well as a slowing down in the rate of growth of" a tumour including metastases. Such measures can be effective in prolonging and/or enhancing the quality of life and relieving the symptoms of the disease.

Compounds of the formula of the present invention in which Y is not a group of formula (II) may be used in a method of treatment of neoplastic disease in a patient, which method comprises administering to a patient in need of treatment an effective amount of a compound of formula The compound may be administered in the form of a pharmaceutical composition.

SUBSTITUTE SHEET (RULE 26) WO 98/25898 PCT/NZ97/00166 16 While the exact dose of the compound will be at the discretion of the physician, taking account of the condition and needs of the patient, typical doses will be in the range of from about 0.1 to 200 mg/Kg, preferably about from 10 to 100 mg/Kg per patient per day.

ADEPT therapy The antibody/enzyme conjugate for ADEPT can be administered simultaneously but it is often found preferable, in clinical practice, to administer the enzyme/agent conjugate before the prodrug, e.g. up to 72 hours or even 1 week before, in order to give the enzyme/agent conjugate an opportunity to localise in the region of the tumour target. By operating in this way, when the prodrug is administered, conversion of the prodrug to the cytotoxic agent tends to be confined to the regions where the enzyme/agent conjugate is localised, i.e. the region of the target tumour the premature release of the compound of formula (II) is minimised.

In ADEPT the degree of localisation of the enzyme/agent conjugate (in terms of the ratio of localized to freely circulating active conjugate) can be further enhanced using the clearance and/or inactivation systems described in W089/10140. This involves, usually following administration of the conjugate and before administration of the prodrug, the administration of a component (a "second component") which is able to bind to the such part of the conjugate so as to inactivate the enzyme and/or accelerate the clearance of the conjugate from the blood. Such a component may include an antibody to the enzyme component of the system which is capable of inactivating the enzyme.

The second component may be linked to a macromolecule such as dextran, a liposome, albumin, macroglobulin or a blood group 0 erythrocyte so that the second component is restrained from leaving the vascular compartment. In addition or as an alternative, the SUBSTITUTE SHEET (RULE 26) WO 98/25898 PCT/NZ97/00166 17 second component may include a sufficient number of covalently bound galactose residues, or residues of other sugars such as lactose or mannose, so that it can bind the conjugate in plasma but be removed together with the conjugate from plasma by receptors for galactose or other sugars in the liver. The second component should be administered and designed for use such that it will not, to any appreciable extent, enter the extravascular space of the tumour where it could inactivate localised conjugate prior to and during administration of the prodrug.

In ADEPT systems, the dose of the prodrug and conjugate will ultimately be at the discretion of the physician, who will take into account such factors as the age, weight and condition of the patient. Suitable doses of prodrug and conjugate are given in Bagshawe et al. Antibody, Immunoconjugates, and Radiopharmaceuticals (1991), 4, 915-922. A suitable dose of conjugate may be from 500 to 200,000 enzyme units/m 2 20,000 enzyme units/m 2 and a suitable dose of prodrug may be from about 0.1 to 200 mg/Kg, preferably about from 10 to 100 mg/Kg per patient per day.

In order to secure maximum concentration of the conjugate at the site of desired treatment, it is normally desirable to space apart administration of the two components by at least 4 hours. The exact regime will be influenced by various factors including the nature of the tumour to be targeted and the nature of the prodrug, but usually there will be an adequate concentration of the conjugate at the site of desired treatment within 48 hours.

The ADEPT system when used with nitroreductase also preferably comprises a suitable cofactor for the enzyme. Suitable cofactors include a riboside or ribotide of nicotinic acid or nicotinamide.

The antibody/enzyme conjugate may be administered by any suitable route usually used in ADEPT therapy. This includes SUBSTITUTE SHEET (RULE 26) WO 98/25898 PCT/NZ97/00166 18 parenteral administration of the antibody in a manner and in formulations similar to that described in section F(iv) below.

F(ii): GDEPT therapy For use of the vectors in therapy, the vectors will usually be packaged into viral particles and the particles delivered to the site of the tumour, as described in for example Ram et al (ibid).

The viral particles may be modified to include an antibody, fragment thereof (including a single chain) or tumour-directed ligand to enhance targeting of the tumour. Alternatively the vectors may be packaged into liposomes. The liposomes may be targeted to a particular tumour. This can be achieved by attaching a tumourdirected antibody to the liposome. Viral particles may also be incorporated into liposomes. The particles may be delivered to the tumour by any suitable means at the disposal of the physician.

Preferably, the viral particles will be capable of selectively infecting the tumour cells. By "selectively infecting" it is meant that the viral particles will primarily infect tumour cells and that the proportion of non-tumour cells infected is such that the damage to non-tumour cells by administration of a prodrug will be acceptably low, given the nature of the disease being treated.

Ultimately, this will be determined by the physician.

One suitable route of administration is by injection of the particles in a sterile solution. Viruses, for example isolated from packaging cell lines may also be administered by regional perfusion or direct intratumoral direction, or direct injection into a body cavity (intracaviterial administration), for example by intraperitoneum injection.

The exact dosage regime for GDEPT will, of course, need to be determined by individual clinicians for individual patients and this, in turn, will be controlled by the exact nature of the prodrug SUBSTITUTE SHEET (RULE 26) WO 98/25898 PCT/NZ97/00166 19 and the cytotoxic agent to be released from the prodrug but some general guidance can be given. Chemotherapy of this type will normally involve parenteral administration of modified virus and administration by the intravenous route is frequently found to be the most practical.

In GDEPT systems the amount of virus or other vector delivered will be such as to provide a similar cellular concentration of enzyme as in the ADEPT system mentioned above. Typically, the vector will be administered to the patient and then the uptake of the vector by transfected or infected (in the case of viral vectors) cells monitored, for example by recovery and analysis of a biopsy sample of targeted tissue. This may be determined by clinical trials which involve administering a range of trial doses to a patient and measuring the degree of infection or transfection of a target cell or tumour. The amount of prodrug required will be similar to or greater than that for ADEPT systems.

In using a GDEPT system the prodrug will usually be administered following administration of the vector encoding an enzyme. Suitable doses of prodrug are from about 0.1 to 200 mg/Kg, preferably about from 10 to 100 mg/Kg per patient per day.

F(iii): Administration of drug or prodrug While it is possible for the compounds of formula or the prodrugs of where Y is a group formula (II) to be administered alone it is preferable to present them as pharmaceutical formulations.

The formulations comprise the compounds, together with one or more acceptable carriers thereof and optionally other therapeutic ingredients. The carrier or carriers must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipients thereof, for example, liposomes. Suitable liposomes include, for example, those SUBSTITUTE SHEET (RULE 26) WO 98/25898 PCT/NZ97/00166 comprising the positively charged lipid dioleyloxy)propyl]-N,N,N-triethylammonium (DOTMA), those comprising dioleoylphosphatidylethanolamine (DOPE), and those comprising (n'N'-dimethylaminoethane)-carbamoyl]cholesterol (DC-Chol).

Formulations suitable for parenteral or intramuscular administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats, bactericidal antibiotics and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents, and liposomes or other microparticulate systems which are designed to target the compound to blood components or one or more organs. the formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water, for injections, immediately prior to use.

Injection solutions and suspensions may be prepared extemporaneously from sterile powders, granules and tablets of the kind previously described.

It should be understood that in addition to the ingredients particularly mentioned above the formulations may include other agents conventional in the art having regard to the type of formulation in question. Of the possible formulations, sterile pyrogen-free aqueous and non-aqueous solutions are preferred.

The doses may be administered sequentially, eg. at daily, weekly or monthly intervals, or in response to a specific need of a patient. Preferred routes of administration are oral delivery and injection, typically parenteral or intramuscular injection or intratumoural injection.

The exact dosage regime will, of course, need to be determined SUBSTITUTE SHEET (RULE 26) WO 98/25898 PCT/NZ97/00166 21 by individual clinicians for individual patients and this, in turn, will be controlled by the exact nature of compound of formula (I) but some general guidance can be given. Typical dosage ranges generally will be those described above which may be administered in single or multiple doses. Other doses may be used according to the condition of the patient and other factors at the discretion of the physician.

The following Examples illustrate the invention.

Example 1. Preparation of l-(E)-4-butvramido-l-methvl-2pyrroleacryloyl)-3-(chloromethvl)-6-nitroindoline 6-amino-l- [(E)-4-butyramido-1-methvl-2-pyrroleacrvloly]-3- (chloromethvl)indoline and 1-[(E)-4-butvramido-l-methvl-2pyrroleacrvlolvl-3-(chloromethvl)-6-[(4-nitrobenzvloxv)carbonvl]aminoindoline (8a) by the Method of Scheme 1.

A mixture of 1-methyl-4-nitro-2-pyrrolecarboxaldehyde

[P.

Fournari, Bull. Soc. Chem. Fr. 1963, 488-491] (0.24 g, 1.56 mmol), methyl triphenylphosphorylidene acetate (0.57 g, 1.71 mmol) and benzene (25 mL) was heated under reflux for 24 h. Purification by dry flash column chromatography, eluting with a gradient of Et20 in CH 2 C12, gave (E)-methyl l-methyl-4-nitro-2-pyrroleacrylate as a bright yellow solid (0.33 g, 100%) mp 146- 147'C. 1H NMR (CDC1 3 6 7.55 J 1.8 Hz, 1 H, 7.47 J 15.8 Hz, 1 H, 7.07 J 1.8 Hz, 1 H, 6.27 J 15.8 Hz, 1 H, Ha) 3.77, 3.75 (2xs, 3 H each, C02CH 3

NCH

3 13 C NMR 6 166.9 (CO 2 136.6, 129.7 130.3, 125.4 117.8, 106.0 (CH=CH), 51.8 (C02CH 3 35.3 (NCH 3 Anal. Calculated for C 9

H

10

N

2 0 4 C, 51.4; H, 4.8; N, 13.3. Found: C, 51.4; H, 4.7; N, 13.3%.

Alternatively, a solution of 1 (0.20 g, 1.30 mmol), malonic acid (0.68 g, 6.5 mmol) and piperidine (2 drops) in pyridine (2 mL) was stirred at room temperature at for 20 h and at 100'C for 4 h, then 30% aqueous H 2

SO

4 (10 mL) was added. The precipitate that formed was removed by filtration and washed with water to give l-methyl-4-nitro-2-pyrroleacrylic acid as fine yellow needles (0.23 g, 92%) 1 H NMR [(CD 3 2 SO] 6 12.35 (br s, 1 H, COH), 8.13 (d, SUBSTITUTE SHEET (RULE 26) WO 98/25898 PCT/NZ97/00166 22 J 1.9 Hz, 1 H, 7.44 J 15.9 Hz, 1 H, 7.41 J 1.9 Hz, 1 H, 6.46 J 15.9 Hz, 1 H, 3.79 3 H, NCH3). 13 C NMR 6 167.4 (CO 2 135.3, 129.9 130.6, 127.0, 118.6, 105.8 5, a, 34.8 (NCH 3 Anal. Calculated for

C

8

H

8

N

2 0 4 C, 49.0; H, 4.1; N, 14.3. Found: C, 49.0; H, 4.0; N, 14.1%.

Dimethyl sulfate (0.12 mL) was added to a solution of 3 (0.10 g, 0.51 mmol) and NaHCO 3 (0.10 g, 0.61 mmol) in methanol-water (5:1, 12 mL) at reflux, and heating continued for 1 h. The mixture was diluted with water (50 mL) and extracted with EtOAc (3x25 mL). The combined extracts were washed with water (2x50 mL), dried (brine, MgSO 4 and evaporated. The residue was purified by dry-flash column chromatography, eluting with 0-5% Et20 in CH 2 C1 2 to give 2 (63 mg, 59%).

A refluxing solution of 2 (50 mg, 0.24 mmol) in aqueous MeOH (1:12.5, 5.4 mL) was treated with iron powder (70 mg, 1.25 mmol) and butyric anhydride (0.40 mL, 2.45 mmol). After 30 min further butyric anhydride (0.10 mL, 0.61 mmol) was added, and 45 min after the addition of the iron, the mixture was allowed to cool and the solids were removed by filtration and washed with MeOH and water. The combined filtrates were diluted with water (25 mL) and extracted with EtOAc (3x25 mL). The combined extracts were washed sequentially with water, saturated aqueous NaHCO 3 water, and brine, then dried (MgSO 4 and evaporated. Dry-flash column chromatography, eluting with a gradient of 0-50% EtOAc in CH 2 C1 2 gave (E)-methyl 4butyramido-l-methyl-2-pyrroleacrylate (45 mg, 75%) as cream plates, mp 109-110'C. 1 H NMR (CDC13) 6 8.0-7.4 (mobile br s, 1 H, NH), 7.51 J 15.6 Hz, 1 H, 7.31 J 1.8 Hz, 1 H, H- 6.39 J 1.8 Hz, 1 H, 6.03 J 15.6 Hz, 1 H, H-a), 3.72, 3.62 (2xs, 3 H each, CO2CH 3

NCH

3 2.27 J 7.4 Hz, 2 H,

CH

2

CH

2

CH

3 1.71 (sx, J 7.4 Hz, 2 H, CH 2

CH

2

CH

3 0.96 J 7.4 Hz, 3 H, CH 2

CH

2

CH

3 13C NMR 6 170.3, 168.1 (NHCO, C0 2 131.9, 118.5, 112.5, 102.0 5, a, 126.7, 123.5 51.5 (C0 2

CH

3 38.8 (NCH 3 34.2 (CH 2

CH

2

CH

3 19.1 (CH 2

CH

2

CH

3 13.7

(CH

2

CH

2

CH

3 Anal. Calculated for C 13

H

18

N

2 0 3 C, 62.4; H, 7.3; N, 11.2. Found: C, 62.1; H, 7.6; N, 11.0%.

A solution of 4 (0.167 g, 0.667 mmol) and 0.2 M aqueous NaOH SUBSTITUTE SHEET (RULE 26) WO 98/25898 PCT/NZ97/00166 23 (5.7 mL, 1.13 mmol) in MeOH (10 mL) was heated under reflux for min. The mixture was cooled to O'C, 2 M aqueous HC1 (0.67 mL, 1.33 mmol) was added, and the mixture was poured onto ice (50 The precipitate that formed was collected by filtration and washed with water to give (E)-4-butyramido-l-methyl-2-pyrroleacrylic acid as yellow needles (0.133 g, 85%) mp 74-76'C (dec.) and 165-166'C (with evolution of gas). 1H NMR [(CD 3 2 SO0 6 12.02 (br s, 1 H, CO 2 9.76 (br s, 1 H, CONH), 7.44 J 15.6 Hz, 1 H, 7.27 J 1.6 Hz, 1 H, 6.53 J 1.6 Hz, 1 H, 6.02 J 15.6 Hz, 1 H, 3.66 3 H, NCH 3 2.19 J 7.3 Hz, 2 H, CH 2

CH

2

CH

3 1.57 (sx, J 7.3 Hz, 2 H, CH 2

CH

2

CH

3 0.88 J 7.3 Hz, 3 H,

CH

2

CH

2

CH

3 13 C NMR 6 169.2, 168.0 (NHCO, CO 2 131.9, 117.8, 113.6, 101.9 5, a, 125.8, 124.2 37.5 (CH 2

CH

2

CH

3 33.6 (NCH3), 18.7 (CH 2

CH

2

CH

3 13.6 (CH 2

CH

2

CH

3 Anal. Calculated for C1 2 H16N 2 0 4 C, 61.0; H, 6.8; N, 11.9. Found: C, C, 60.8; H, 8.4; N, 11.7%.

A mixture of 5 (37 mg, 0.16 mmol), 3-(chloromethyl)-6nitroindoline [prepared by in situ acid hydrolysis of l-(tertbutyloxycarbonyl)-3-chloromethyl-6-nitroindoline] [for preparation see WO 88/04659 and WO 91/19624](34 mg, 0.16 mmol), 1-(3dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI, 92 mg, 0.48 mmol) and DMA (5 mL) were stirred at room temperature for 20 h.

The mixture was diluted with water (50 mL) and extracted with EtOAc (4x20 mL). The combined extracts were washed with water (3x50 mL) and brine, dried over MgS04, and evaporated. Dry-flash column chromatography, eluting with a gradient of 0-100% EtOAc in CH 2 C1 2 gave 4 -butyramido-1-methyl-2-pyrroleacryloyl)-3- (chloromethyl)-6-nitroindoline as a yellow solid (43 mg, 62%).

'H NMR (CDC1 3 6 9.09 (br s, 1 H, 7.94 (dd, J 8.2, 2.2 Hz, 1 H, 7.77 J 14.9 Hz, 1 H, 7.36 J 8.2 Hz, 1 H, 7.24 J 1.6 Hz, 1 H, 7.19 (br s, 1 H, NH), 6.66 J 1.6 Hz, 1 H, 6.47 J 14.9 Hz, 1 H, 4.46 J 10.7, 9.8 Hz, 1 H, 4.25 J 10.7, 5.0 Hz, 1 H, H- 3.95-3.61 3 H, CH 2 C1, 3.70 3 H, NCH3), 2.32 J 7.4 Hz, 2 H, CH 2

CH

2

CH

3 1.75 (sx, J 7.4 Hz, 2 H, CH 2

CH

2

CH

3 1.00 J 7.4 Hz, 3 H, CH 2

CH

2

CH

3 SUBSTITUTE SHEET (RULE 26) WO 98/25898 PCT/NZ97/00166 24 A solution of 7 (28 mg, 0.065 mmol) and AcOH (0.02 mL, 0.33 mmol) in MeOH (14 mL) and water (2.8 mL) was treated at reflux with iron powder (20 mg, 0.36 mmol). After 20 min, further iron powder mg, 0.90 mmol) and AcOH (0.5 mL, 0.87 mmol) were added, and after an additional 40 min the mixture was poured into dilute aqueous NaHCO 3 (100 mL) and extracted with EtOAc (4x20 mL). The combined extracts were washed with dilute aqueous NaHCO 3 (2x50 mL), dried (brine, MgSO 4 and evaporated. Multiple sweep preparative thin layer chromatography, eluting with EtOAc, gave 6-amino-l-((E)- 4-butyramido-1-methyl-2-pyrroleacryloyl]-3-(chloromethyl)indoline (12 mg, 45%) as a bright yellow solid. 1H NMR (CDC1 3 7.76 (br s, 1 H, 7.68 J 14.9 Hz, 1 H, H-0) 7.35 (br s, 1 H, NH), 7.24 J 1.7 Hz, 1 H, 6.97 J 8.0 Hz, 1 H, H-4), 6.59 (br s, 1 H, 6.49 (br d, J 14.9 Hz, 1 H, 6.37 (dd, J 8.0, 2.2 Hz, 1 H, 4.29 (dd, J 8.0, 2.2 Hz, 1 H, H- 4.11 (dd, J 10.8, 4.4 Hz, 1 H, 3.74 (dd, J 10.7, 4.3 Hz, 1 H, CHHC1), 3.64 3 H, NCH 3 3.71-3.59 1 H, 3.49 (dd, J 10.7, 9.7 Hz, 1 H, CHHC1), 2.29 J 7.4H z, 2 H,

CH

2

CH

2

CH

3 1.73 (sx, J 7.4 Hz, 2 H, CH 2

CH

2

CH

3 0.98 J 7.4 hz, 3 H, CH 2

CH

2

CH

3 4-Nitrobenzyl chloroformate (52 mg, 0.24 mmol) was added to a solution of 8 (48 mg, 0.12 mmol) in dry pyridine (6mL) and the yellow solution was stirred at 20'C. More 4-nitrobenzyl chloroformate (52 mg, 0.24 mmol) was added after 30 min. After a further 1 h water was added and the mixture stirred for 30 min until the oil that separated had solidified. The solid was filtered off, washed with water, dried, and triturated with hot EtOAc to give 1- [(E)-4-butyramido-1-methyl-2-pyrroleacryloyl]-3-(chloromethyl)-6- [(4-nitrobenzyloxy)carbonyl]aminoindoline (8a) (49 mg, 71%) as a yellow solid, mp 207-209.5'C. 1H NMR [(CD 3 2 SO] 6 9.91 1 H, NH), 9.76 1 H, NH), 8.40 1 H, 8.27 J 8.7 Hz, 2 H, ArHo to NO 2 7.70 J 8.7 Hz, 2 H, ArHm to NO 2 7.54 J 15.0 Hz, 1 H, H-0) 7.28 J 8.2 Hz, 1 H, 7.22 J Hz, 1 H, 7.16 J 8.2 Hz, 1 H, 6.71 J 1.4 Hz, 1 H, 6.64 J 15.0 Hz, 1 H, 5.30 2 H, ArCH 2 4.48-4.39 1 H, 4.12 (dd, J 10.5, 4.1 Hz, 1 H, SUBSTITUTE SHEET (RULE 26) WO 98/25898 PCT/NZ97/00166 ArCH 2 4.48-4.39 1 H, H1-2), 4.12 (dd, J =10.5, 4.1 Hz,1 1 H, H1-2) 3. 98 -3 92 (in, .1 H, CHCH 2 C1) 3.-85 3. 76 (i,2 11, CHCH 2 C1), 3.6 8 3H1, NCH 3 2.20 Ct, J =7.3 Hz, 2 H, CH 2

CH_

2

CH

3 1.58. (sx,J= 7.4 Hz, 2 H, CH 2

CH

2

CH

3 0.89 Ct, J 7.4 Hz, 3 H, CH 2

CH

2

CH

3 Example 2. Preparation of 1-f CE)-3-(1-methvlpvrrole-2.

carboxamido) cinnamoyll 3 -chloromethvl-6-nitroindoline (12) by the method of Scheme 2.

A mixture of methyl (E)-3-aminocinnamate (1.20 g, 6.7 7 mmol), 1-methylpyrrole-2-carboxylic acid (0.89 g, 7.11 mmcl) and EDCI.HCl (1.56 g, 8.14 mmol) in pyridine (8 mL) was stirred at for 2.5 h and then cooled and diluted with water. The precipitated semi-solid was dissolved in C11 2 C1 2 the solution was washed with N Rd1 (2x) and water (2x) and then dried and concentrated under reduced pressure below 30*C. The residue was chromatographed on silica gel, eluting with CH2Cl2/EtOAc to yield a solid which was triturated with i-Pr 2 O/petroleum ether to give thermally unstable methyl CE) (l-methylpyrrole-2-carboxamido) cinnamate 42 g, 74%) mp 89-90'C. 1H1 NMR C(CD 3 2 S0J 6 9.83 1 NH) 8.01 Cd, J 1.4 Hz, 1 H, H1-2), 7.76 (dt, J 7.8, 1.4 Hz, 1 H, 11-4), 7.63 Cd, J =16.0 Hz, 111, PhCH=CH), 7.45-7.35 2 11, H1-5,6), 7.05 (dd, J 4.0, 1.7 Hz, 1 H, 11-pyrrole), 7.03 J Hz, 1 H, 11-pyrrole), 6.54 J 16.0 Hz, 1 H, Ph CH=CM), 6.11 (dd, J 3.8, 2.6 Hz, 1 H, 11-pyrrole) 3.89 Cs, 3 H, NCH 3 3.74 Cs, 3 H, C0 2

CH

3 .A solution of Cs 2

CO

3 (3.26 g) in 1120 (2 mL) was diluted with MeOH (8 mL) and ester 10 (0.91 g, 3.2 minol) was added. The mixture was heated under ref lux for 2.5 h then cooled and acidified with Rd1. The precipitated solid was collected, dried and dissolved in warm EtOAc. The solution was concentrated to a small volume under reduced pressure below 40*C and then diluted with i-Pr 2 0 to provide CE) lmtyprol--abxmiocnai acid (11) (0.79 g, 91%) mp 202-204'C. 1H NMR [C(CD 3 2 S0J 6 12.44 Cbr s, 1 H, CO 2 R) 1 9. 82 Cs, 1 H, NH), 7.99 Cs, 1 H, 11-2), 7.79-7.73 1 H, H1-4), 7.56 Cd, SUBSTITUTE SHEET (RULE 26) WO 98/25898 PCT/NZ97/00166 26 J 16.0 Hz, 1 H, PhCH=CH), 7.40-7.34 (Mn, 2 H, H1-5,6), 7.05 (dd, J 1.7 Hz, 1 H, 1-pyrrole), 7.02 J =2.0 Hz, 1 H, H-pyrrole), 6.44 Cd, J 16.0 Hz, 1 H, PhCH=CH), 6.11 (dd, J 3.8,2.6 Hz, 1 H, 1-pyrrole), 3.89 3 H, NCH 3 1- (tert-Butyloxycarbonyl) -3 -chlorolnethyl-6-nitroindole (156 mg, 0.50 mmcl) was stirred in HC1-saturated dioxane (5 mL) at for 2 h, and the mixture was then evaporated to dryness under high vacuum below 25*C to give crude 3-chloromethyl-6-nitroindoline Acid 11 (135 mgT, 0.50 mmol), EDCI.HC1 (240 mg, 1.25 mmol) and DMA (1.5 mL) were then added in sequential fashion and the mixture was stirred at 20*C for 2 h. Dilution with water provided the crude product which was recrystallised twice from EtOAc to give 1-[CE)-3- Cl-methylpyrrole-2-carboxamido) -cinnamoylj -3-chloromethyl-6nitroindole (12) (166 mg, 729.), mp 215*C. 1 H NMR [(CD 3 2 So] 6 9.86 Cs, 1 H, NH), 8.97 1 H, 8.03-7.96 1 H, 8.00 Cs, 1 H, 7.80 Cd, J 8.0 Hz, 1 H, 7.70 Cd, J 8.3 Hz, 1 H, 7.69 J =15.4 Hz, 1 H, PhCH=CH), 7.54 J 7.4 Hz, 1 H, H-6' 7.41 Ct, J 7.9 Hz, 1 H, H1-5') 7.11 Cd, J 15.4 Hz, 1 H, PhCH=CH), 7.1-7.04 (in, 2 H, H-pyrrole), 6.12 J =3.1 Hz, 1 H, H-pyrrole), 4.66 Ct, J 10.0 Hz, 1 H, 4.34 Cdd, J 10.6, 5.1 Hz, 1 H, H1-2), 4.15-3.99 Cm, 3 H, H-3, CH 2 C1), 3.90 3 H, NCH 3 Example 3. Preparation of 1- I E) (acetvjlamino) cinnamovl] -3chloroinethvl-6-nitroindoline by the method of Scheme 2.

Similar reaction of (E)-3-(acetylamino)cinnamic acid and crude 3-chloromethyl-6-nitroindoline Cprepared as in Example 2) gave a crude product which was recrystallised. from DMF/MeOH/H 2 0 to give 1- [CE) Cacetylamino) cinnamoyl] -3-chloromethyl-6-nitroindoline (13) mp 229-230'C. 1H1 NMR [(CD 3 2 SO] b 10.06 Cs, 1 H, NH), 8.97 Cs, 1 7.99 Cdd, J 8.3, 2.3 Hz, 1 H, H1-5) .7.86 Cs, 1 H, 7.73-7.61 Cm, 2 H, 7.66 Cd, J 15.3 Hz, 1 H, SUBSTITUTE SHEET (RULE 26) WO 98/25898 PCT/NZ97/00166 27 PhCH=CH), 7.53 J 7.8 Hz, 1 H, 7.38 J 7.9 Hz, 1 H, 7.08 J 15.4 Hz, 1 H, PhCH=CH), 4.65 J 10.0 Hz, 1 H, 4.33 (dd, J 10.7, 5.2 Hz, 1 H, 4.14-4.00 3 H, H-3,

CH

2 C1), 2.07 3 H, CH 3 Example 4. Biological Activity The compounds of Formula I show cytotoxicity to mammalian tumour cells, and are thus of interest as anticancer drugs. The compounds of formula I in which Y is NO 2 or a group of formula II also show high levels of activation by the isolated E. coli NR2 nitroreductase enzyme.

To evaluate the activity of a compound UV4 cells were maintained in exponential phase growth (doubling times 14 and 15 h respectively) using Alpha MEM containing fetal calf serum (10% v/v) without antibiotics, and were subcultured twice weekly by trypsinization. Bulk cultures were prepared for experiments by seeding cells in spinner flasks at 104 cells/mL in the above medium with addition of penicillin (100 IU/mL) and streptomycin (100 g/mL). Cultures were initiated in 96-well microtiter trays to give 200 (AA8) or 300 (UV4) cells in 0.05 mL per well. After growth in a C02 incubator for 24 h, drugs were added in culture medium, using serial two-fold dilutions to provide duplicate cultures at five different concentrations for each of eight drugs (plus eight controls) per tray. After 18 h drugs were removed by washing cultures three times with fresh medium, and the trays were incubated for a further 78 h. Cell density was then determined by staining with methylene blue as described [Finlay, Baguley,. B.C.; Wilson, W.R. Anal. Biochem., 1984, 139: 272-277]. The IC 50 was calculated as the drug concentration providing 50% inhibition of growth relative to the controls.

To evaluate the activation of the compound by E. coli SUBSTITUTE SHEET (RULE 26) WO 98/25898 PCT/NZ97/00166 28 nitroreductase 2 (NR2) the experiment was repeated but in addition purified E. coli nitroreductase enzyme (1 Ag/mL) and NADH (1 mM, as cofactor) was added during the entire time of the incubation. As a comparison the experiment was also repeated but with the addition only of NADH and not NR2.

The results are shown in Table 1 below. Where multiple determinations were carried out the IC,, is given as an average SEM. Where one determination only was carried out a single ICso value is given.

TABLE 1 Compound IC 5 0 (nM) IC 5 0 (nM) IC 5 0 (nM) drug Ratio* (see drug alone drug NADH NADH NR2 Schemes) 7 2940+320 1080+340 43+4 70+13 8 38 24 35 1.1 12 ca. 5000 ca. 13 335 339 74±23

IC

5 0 drug alone/IC 5 0 drug NADH NR2.

experiment ratios.

Values are intra- SUBSTITUTE SHEET (RULE 26)

Claims

1. A compound which is a 6-substituted indoline of the formula X (I) N Ht o Y wherein: X is halogen or OS0 2 R where R represents H or Ci 5 alkyl optionally substituted with from 1 to 4 hydroxyl, acid (COOH) or amino groups which amino may be optionally substituted by one or two CI 5 alkyl groups; Y is NO 2 N 3 NHOH, NHR, NRR, N=NR, N(O)RR, SR or SSR, where R is defined as above, but that in the case where Y is SSR or N=NR, then R can also be another moiety of formula or Y is a group of formula: S-NR 2 A NR S3 (II) ~NO 2 here R is defined above, and A may be a group CONHR, NHCOR or OR bij' 4re R is as defined above at any one of positions 2 or 3; *e~o e** Ht is a 5 or 6 membered carbocycle or heterocycle containing up to two atoms selected from N, 0 or S, the carbocycle or heterocycle being optionally substituted by a group Q wherein either Q is one or two of H, OR or NRR where R is defined as above (which may be the same or different when Q is two) or Q is a group CONHJ 1 NHCOJi, NHCOOJ 1 or NHCONHJ 1 where J 1 is either a group R as defined above or a 5 or 6 membered carbocycle or heterocycle containing up to two atoms selected from N. O or S and can bear a substituent R, OR, NHCOR, NHCOOR or NHCORHR where R is as defined above, wherein if Ht is a pyrrol-2-yl group, then the pyrrolyl group may bear an N- methyl group; or a physiologically functional derivative thereof.

2. A compound as claimed in claim 1 in which Y is NO 2 or a group of formula II.

3. A compound as claimed in claim 1 or claim 2 wherein X represents Cl.

4. A compound as claimed in any one of claims 1 to 2 in which Ht is phenyl or pyrrolyl.

5. A compound as claimed in any one of claims 1 to 4 in which 20 Q is NHCOR where R is Ci, 4 alkyl or NHCOJ 1 where J1 is an optionally substituted 5- or 6-membered heterocycle.

6. A compound as claimed in claim 5 in which J 1 is pyrrol-2- yl, optionally substituted on the nitrogen atom by C 1 4 akyl.

7. 4 -butyramido-l-methyl-2-pyrroleacryloyl)-3- *oo 25 (chloromethyl)-6-nitroindoline.

8. 6-lmino-l-[(E)- 4 -butyramido-l-methyl-2-pyrroleacryloyl]-3- (chloromethyl)indoline.

9. 4 -butyramido-l-methyl-2-pyrroleacryloyl]-3- (chloromethyl-6-[(4-nitrobenzyloxy) carbonyl]-aminoindoline.

10. 3 -(l-methylpyrrole-2-carboxamidio)cinnamoyl]-3- chloromethyl-6-nitroindoline.

11. A two component system for the treatment of neoplastic disease which comprises: ST -4E OF F~ A vector encoding and capable of expressing a nitroreductase enzyme in a tumour cell; and (ii) a compound according to claim 1, in which Y is NO 2 N(O)RR, or a moiety of formula II.

12. A two compound system for the treatment of neoplastic disease which comprises a tumour-directed antibody linked to a nitroreductase enzyme; and (ii) a compound according to claim 1, in which Y is NO 2 N(O)RR, or a moiety of formula II.

13. A composition comprising a compound according to any one of claims 1 to 10 together with a pharmaceutically acceptable carrier or diluent.

14. A compound according to any one of claims 1 to 10, a system according to claims 11 or 12, or a composition according to claim 13 for use in a method of treatment of the human or animal body. A method of treating neoplastic disease which comprises administering to a patient in need of treatment an effective amount 20 of a compound according to any one of claims 1 to 10, a system according to claims 11 or 12, or a composition according to claim 13. 0* 0 *4 o•. go• o• ooooe